Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

此外，瑞银此前研报指出，将康希诺生物2026及2027年收入预测分别上调22%及下调9%。康希诺生物 管理层表示，MCV4疫苗在今年首三季贡献6.62亿元人民币(下同)收入，同比增长约28%，主要因适用 年龄群扩大，以及持续渠道渗透。MCV4已于第三季开始出口至印尼，该行估计今年将录得数百万元销 售额。另外，PCV13i自今年中上市以来，已进入约12个省份，管理层目标在年底前覆盖半数省份，并 于明年拓展至其他市场。 消息面上，康希诺生物发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)近日于印度尼西亚正 式启动I期临床试验，并完成I期临床试验首例受试者入组。据悉，I期临床试验于印度尼西亚开展，目的 是在18至49岁的成年人中探究接种一剂吸入用结核病加强疫苗的安全性和免疫原性。 康希诺生物(06185)涨超5%，截至发稿，涨5.03%，报46.38港元，成交额1611.81万港元。 ...

人民财讯11月13日电，康希诺(688185)11月13日公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体) (简称"吸入用结核病加强疫苗")近日于印度尼西亚启动I期临床试验，并完成Ⅰ期临床首例受试者入组。 ...